News Releases - NervGen Pharma
WEBAug 2, 2024 · NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen …
See results only from nervgen.comHomepage - NervGen Phar…
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company …
NervGen Pharma Announces …
NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic …
Homepage - NervGen Pharma
WEBAug 22, 2024 · NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair …
NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th …
WEB1 day ago · Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company …
NervGen Pharma Announces First Subject Dosed in Landmark …
WEBSep 25, 2023 · NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. …
NervGen Pharma Reports Q2 2024 Financial Results and …
WEBAug 22, 2024 · NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair …
NervGen Pharma Announces First Subject Dosed in Landmark …
WEBSep 25, 2023 · NervGen (TSXV: NGEN) (OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system …
- People also ask
NervGen Pharma’s NVG-291-R Demonstrates Significant
WEBJul 28, 2022 · NervGen’s lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial. The company’s initial target indications are spinal cord injury, Alzheimer’s disease …
NervGen Pharma Announces Intent to Conduct
WEBJan 10, 2022 · Following completion of the Phase 1 study in healthy males and the premonopausal females, NervGen intends to proceed to the planned Phase 1b/2 safety and efficacy studies in spinal cord injury ...
NervGen Pharma on Track to Complete Enrollment, Deliver Data
WEBFeb 15, 2024 · NervGen Pharma Corp., a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today …
NervGen Cleared to Enroll Final Group in Trial of NVG-291
WEBMay 13, 2022 · NervGen Pharma has received approval to enroll a third and final group of healthy volunteers in the multiple ascending dose (MAD) segment of its Phase 1 clinical …
Skip to content
